How many drugs treat Hypercortisolism?

Drug Landscape tracks 5 marketed treatments for Hypercortisolism (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypercortisolism.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypercortisolism — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypercortisolism (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypercortisolism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Isturisa	OSILODROSTAT	Recordati	Cortisol Synthesis Inhibitor	Cytochrome P450 11B2, mitochondrial	2020-01-01
Signifor	PASIREOTIDE	Recordati	Somatostatin Analog [EPC]	Somatostatin receptor type 5	2012-01-01
Desopan	TRILOSTANE	Bioenvision	trilostane	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2	1984-01-01
Nizoral	ketoconazole	Johnson & Johnson (Janssen)	Azole Antifungal [EPC]	Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1	1981-06-26
Signifor	Signifor	University Hospital Heidelberg		Somatostatin receptor type 1, Somatostatin receptor type 2, Somatostatin receptor type 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Recordati · 2 drugs in Hypercortisolism
Bioenvision · 1 drug in Hypercortisolism
Johnson & Johnson (Janssen) · 1 drug in Hypercortisolism
University Hospital Heidelberg · 1 drug in Hypercortisolism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypercortisolism:

Cite this brief

Drug Landscape (2026). Hypercortisolism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypercortisolism. Accessed 2026-06-10.

Hypercortisolism full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing